News
Podcast: Talking the cure
11 April 2024
Our team is always thinking about how to foresee and conquer the most significant industry issues facing our clients. In 2020, we launched the podcast "Talking the Cure" where we cover...
According to Global Investigations Review 100 (GIR), we are "One of the world's best investigations and white-collar practices." We work with you to limit the impact these events can have on your business. Our strength lies in managing the effects of an investigation – often where there is a multijurisdictional element.
Regulatory investigations; allegations of fraud, bribery, and corruption; sanctions and money laundering; whistle-blower complaints; dawn raids – multinationals and their executives face these and other threats to their businesses and reputations. If you get hit, you’ll need a strong investigative team.
We know the issues you need to watch out for
Our award-winning team handles all issues relating to enforcement, whistle-blowing, criminal liability, regulatory violations, tax investigations, and asset recovery. We pursue and defend claims against executive boards, and we craft internal programs and policies that comply with global legislation, such as the Foreign Corrupt Practices Act and the UK Bribery Act. Local matters often give rise to international legal risks and investigations. Our team handles cross-border work, including in offshore jurisdictions. And we know what it takes to deal with such issues, having teams established in China, Russia, Europe, the Americas, Africa, and the Middle East. Whether this entails freezing assets or managing the interplay between foreign corruption and local jurisdictions, we know your concerns. Says GIR, "Few firms can rival Hogan Lovells' size, reputation and experience in the investigations space."
Representative experience
Successfully defending leading research institutions in an FCA investigation involving multiple federal agencies and over US$1 billion of federal funding.
Defending a medical device company in an FCA qui tam case in which a manager sought damages for alleged kickbacks to physicians.
Advising a radiation therapy client in relation to internal investigations focusing on allegations of corruption and corporate crime, as well as on a full range of compliance matters around the world, including the United States.
Advising a purchaser on anti-bribery risk in relation to its share purchase of a group of healthcare equipment companies.
Acting on behalf of BTA Bank, Kazakhstan's largest bank, in asset recovery litigation concerning US$6 billion, the largest such case in the UK in 2013.
Advising a Fortune 200 company regarding an investigation by the DOJ and SEC into allegations that it paid bribes to secure a contract in China and similar allegations elsewhere.
Defending a pharma company on a substantial U.S. federal criminal investigation in connection with the promotion, marketing, and sale of one of its drugs.
Undertaking an internal investigation of Eletrobras, the largest electric company in Brazil, of allegations related to the Petrobras “Lava Jato” scandal.
Acting for Air Canada in the European Commission's air cargo cartel investigation and related private U.S. and UK litigation.
Investigating management responsibility for the delays to the A380, Airbus’ flagship twin-deck airliner.
We represented a private European bank regarding a Financial Services Authority (FSA) investigation into the adequacy of its anti-corruption control.
We advised a client in connection with an investigation by the UK Serious Fraud Office (SFO) into suspected overseas corruption.
We advised a multinational financial institution regarding a City of London Police investigation into alleged foreign corrupt business practices.
We advised a European paper mill producer regarding strategy and legal action in an internal fraud investigation in China.
We successfully represented one of the world's largest, most recognizable companies when they were barred from contracting with the U.S. government.
We conducted internal reviews of payments for a Fortune 500 pharmaceutical company
Our team advised one of the world's largest insurers in connection with an inquiry by the U.S. Committee on Oversight and Government Reform.
